Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

Buprenorphine

buprenorphine
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Probuphine DEVICE, IMPLANT 74.2 mg      
Belbuca FILM, BUCCAL 75 mcg, 150 mcg, 300 mcg, 450 mcg, 600 mcg, 750 mcg, 900 mcg    
Butrans FILM, EXTENDED RELEASE, TRANSDERMAL 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr, 20 mcg/hr      
Buprenex SOLUTION, INJECTABLE 0.3 mg/mL    
Sublocade SOLUTION, SUBCUTANEOUS 100 mg/0.5 mL, 300 mg/1.5 mL      
Subutex TABLET, SUBLINGUAL 2 mg, 8 mg      
VIEW MORE Opioid Partial Agonists
CLASS
280812
Comments:

ORDERED FORMULATION

FORMULARY INTERCHANGE*

buprenorphine (Buprenex)

  • 0.3 – 0.6 mg solution injectable q3-6 hrs

nalBUPHine (Nubain)

  • 10 mg solution injectable q3-6 hrs

*Interchange is for pain control indication only. When ordered for narcotic withdrawal, BUPRENEX should be dispensed as prescribed (NO SUB).

 

Belbuca is classified as non formulary. Interchange to a similar potency oral morphine ER tablet or solution. Use of Belbuca deferred to after patient discharge. Patients may utilize home supply of medication if deemed necessary while in the hospital.

 

Formulary Interchange
  If Able to Take by Mouth If Unable to Take Tablet By Mouth
Belbuca Dose Morphine ER Dose Morphine 10 mg/5 mL Oral Solution Dose
75 mcg Qday 15 mg Qday 5 mg TID
75 mcg q12h 15 mg q12h 5 mg q4h
150 mcg q12h 30 mg q12h 10 mg q4h
300 mcg q12h 60 mg q12h 20 mg q4h
                                 Morphine 10 mg/5 mL Oral Solution Dose
450 mcg q12h 30 mg q4h, contact prescriber if additional pain control is needed*
600 mcg q12h 30 mg q4h, contact prescriber if additional pain control is needed*
750 mcg q12h 30 mg q4h, contact prescriber if additional pain control is needed*
900 mcg q12h 30 mg q4h, contact prescriber if additional pain control is needed*

 

Butrans patch is classified as formulary, restricted to continuation from home medication reconciliation. The 10 mcg/hr and 20 mch/hr patches will be routinely stocked for inpatient use. If other patch strengths are ordered, the patient's home supply should be utilized. If the patch is unavailable from the patient, the provider should be contacted for an alternative order.

 

Sublocade is non-formulary, not stocked. Contact MD for alternative therapy. Defer to outpatient clinic use. Pain Center does not treat opiate use disorder/addiction.

 

 

Reviewed: October 25, 2011 (BUTRANS); December 17, 2013 (Subutex); 25 October 2016 (Probuphine); 22 May 2018 (Sublocade), 26 May 2020 (Belbuca) July 2025 (Butrans)

Buprenorphine Patch (BUTRANS) Formulary Update.pdf

 

REMS (Butrans): View FDA REMS Info

REMS (Probuphine): View FDA REMS Info

REMS (buprenorphine): Buprenorphine Transmucosal Products for Opioid Dependence (BTOD)Info

REMS (Sublocade): Sublocade (buprenorphine extended-release)

REMS (Subutex): Suboxone/Subutex (buprenorphine and naloxone/buprenorphine)

 

Belbuca medication guide

Butrans medication guide

Sublocade medication guide

Subutex medication guide

Last updated: Jul. 31, 2025






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved